GSK receives marketing authorisation from the European Commission for Revolade (eltrombopag) for low platelet counts
Cinnamon Girl said
Sep 26, 2013
Yes I don`t know why it`s taken so long to be approved in Europe either. I notice it`s been approved by NICE for use within the NHS over here in the UK now. Sounds like it will a very useful medication for certain people, even though it can potentially cause some severe side effects. I have read about them and so can understand why you wanted to avoid it while on treatment even when your platelets levels dropped so low.
Oh yes, the joys of ageing, I know exactly what you mean! We`re all in it together, just keep smiling!
Thanks Malcolm.
mallani said
Sep 26, 2013
Hi Jill,
I'm amazed that it had never been approved before. It's been available here for at least 5 years. It will be great for those who are deemed 'ineligible' for Rx due to low platelets to get them up to an accepted level (120,000 here).
During Rx, personally, I would not touch the stuff, as there have been too many bad stories. Low platelets during Rx is not life-threatening, and mine dropped to 28,000. That's OK as long as you don't run a risk of injury. The general opinion is that the 'quality' of the platelets is very important. Patients over 65yo produce platelets of lower quality ( my doc used to call them 'home-brand') so older people get purpura and ecchymoses from trivial injuries, despite having a normal platelet count. Another of the joys of aging! Cheers.
Cinnamon Girl said
Sep 26, 2013
GSK receives marketing authorisation from the European Commission for additional Revolade (eltrombopag) indication as the first approved treatment for chronic hepatitis C-associated thrombocytopenia
GlaxoSmithKline plc announced today, 24th September, that the European Commission has granted an additional indication for Revolade (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon (IFN)-based therapy.
Yes I don`t know why it`s taken so long to be approved in Europe either. I notice it`s been approved by NICE for use within the NHS over here in the UK now. Sounds like it will a very useful medication for certain people, even though it can potentially cause some severe side effects. I have read about them and so can understand why you wanted to avoid it while on treatment even when your platelets levels dropped so low.
Oh yes, the joys of ageing, I know exactly what you mean! We`re all in it together, just keep smiling!
Thanks Malcolm.
Hi Jill,
I'm amazed that it had never been approved before. It's been available here for at least 5 years. It will be great for those who are deemed 'ineligible' for Rx due to low platelets to get them up to an accepted level (120,000 here).
During Rx, personally, I would not touch the stuff, as there have been too many bad stories. Low platelets during Rx is not life-threatening, and mine dropped to 28,000. That's OK as long as you don't run a risk of injury. The general opinion is that the 'quality' of the platelets is very important. Patients over 65yo produce platelets of lower quality ( my doc used to call them 'home-brand') so older people get purpura and ecchymoses from trivial injuries, despite having a normal platelet count. Another of the joys of aging! Cheers.
GSK receives marketing authorisation from the European Commission for additional Revolade (eltrombopag) indication as the first approved treatment for chronic hepatitis C-associated thrombocytopenia
GlaxoSmithKline plc announced today, 24th September, that the European Commission has granted an additional indication for Revolade (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon (IFN)-based therapy.
See full press release...
http://www.gsk.com/media/press-releases/2013/gsk-receives-marketing-authorisation-from-the-european-commissio1.html